Bridge Biotherapeutics (Korea) Today
| 288330 Stock | KRW 3,940 120.00 2.96% |
Performance2 of 100
| Odds Of DistressLess than 38
|
Bridge Biotherapeutics is trading at 3940.00 as of the 23rd of December 2024, a 2.96 percent decrease since the beginning of the trading day. The stock's open price was 4060.0. Bridge Biotherapeutics has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of November 2024 and ending today, the 23rd of December 2024. Click here to learn more.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. More on Bridge Biotherapeutics
Moving together with Bridge Stock
Moving against Bridge Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bridge Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bridge Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bridge Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology & Medical Research, Healthcare (View all Sectors) |
Bridge Biotherapeutics (288330) is traded on KOSDAQ in Korea and employs 4 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 217.07 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bridge Biotherapeutics's market, we take the total number of its shares issued and multiply it by Bridge Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bridge Biotherapeutics operates under Healthcare sector and is part of Biotechnology & Medical Research industry.
Bridge Biotherapeutics has accumulated about 8.2 B in cash with (21.13 B) of positive cash flow from operations.
Check Bridge Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Bridge Biotherapeutics is W217.07 Billion. Bridge Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Bridge Ownership Details
Bridge Biotherapeutics Risk Profiles
Although Bridge Biotherapeutics' alpha and beta are two of the key measurements used to evaluate Bridge Biotherapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.78 | |||
| Semi Deviation | 5.84 | |||
| Standard Deviation | 7.92 | |||
| Variance | 62.75 |
Bridge Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bridge Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Bridge Biotherapeutics Corporate Management
Elected by the shareholders, the Bridge Biotherapeutics' board of directors comprises two types of representatives: Bridge Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bridge. The board's role is to monitor Bridge Biotherapeutics' management team and ensure that shareholders' interests are well served. Bridge Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bridge Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Taeksang Park | VP CFO | Profile | |
| Gwanghee Lee | VP Director | Profile | |
| SangUk Kang | VP Director | Profile | |
| James Lee | CEO Director | Profile |
Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.